Publication
2nd Circuit defers to executive will on application of sovereign immunity
The Second Circuit recently held that federal common law protections of sovereign immunity did not preclude prosecution of a state-owned foreign corporation.
Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies
The Life Sciences Lawyer Magazine
As the COVID pandemic lumbers on to its third year, there continues to be global disparities in access to the tools (i.e., vaccines and therapeutics) necessary to combat the pandemic.
A core reason behind this disparity is the developing world’s lack of access to the intellectual property (and technical know-how) required to manufacture these vital vaccines and therapeutics. In 2021, the United States announced that it would support the temporary waiver of intellectual property protections for COVID-19 vaccines under the Trade Related Aspects of Intellectual Property Rights (“TRIPS”) Agreement.
This article explores the current controversy around the waiver of intellectual property rights for COVID-19 vaccines and therapeutics and their implications for life sciences companies.
Read the full article from The Life Sciences Lawyer Magazine, "Current controversy around the waiver of intellectual property rights for COVID-19 Vaccines and implications for life sciences companies."
Partner-in-Charge, San Francisco
Email
jason.novak@nortonrosefulbright.com
Recent publications
Publication
Key takeaways from the G7 Competition Summit on Artificial Intelligence
Facing the fast-growing development of AI across the globe, particularly Generative AI (GenAI), the G7 competition authorities and policymakers (Canada, France, Germany, Japan, Italy, the UK and the US) and the European Commission met in Italy on 3-4 October 2024 to discuss the main competition challenges raised by these new technologies in digital markets.
Subscribe and stay up to date with the latest legal news, information and events . . .